Dermata Therapeutics Valuation
| DRMA Stock | USD 1.24 0.06 5.08% |
Today, the firm appears to be overvalued. Dermata Therapeutics shows a prevailing Real Value of $1.05 per share. The current price of the firm is $1.24. Our model computes the value of Dermata Therapeutics from reviewing the firm fundamentals such as Shares Owned By Institutions of 0.84 %, shares owned by insiders of 23.20 %, and Current Valuation of 3.43 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Dermata Therapeutics' valuation include:
Overvalued
Today
Please note that Dermata Therapeutics' price fluctuation is extremely dangerous at this time. Calculation of the real value of Dermata Therapeutics is based on 3 months time horizon. Increasing Dermata Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Dermata Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Dermata Stock. However, Dermata Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.24 | Real 1.05 | Target 6.0 | Hype 1.24 | Naive 1.27 |
The real value of Dermata Stock, also known as its intrinsic value, is the underlying worth of Dermata Therapeutics Company, which is reflected in its stock price. It is based on Dermata Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Dermata Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Dermata Therapeutics helps investors to forecast how Dermata stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dermata Therapeutics more accurately as focusing exclusively on Dermata Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Dermata Therapeutics' intrinsic value based on its ongoing forecasts of Dermata Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Dermata Therapeutics' closest peers. If more than one evaluation category is relevant for Dermata Therapeutics we suggest using both methods to arrive at a better estimate.
Dermata Therapeutics Cash |
|
Dermata Valuation Trend
Comparing Dermata Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Dermata Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Dermata Therapeutics Total Value Analysis
Dermata Therapeutics is currently expected to have valuation of 3.43 M with market capitalization of 6.64 M, debt of 1.97 B, and cash on hands of 10.63 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Dermata Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.43 M | 6.64 M | 1.97 B | 10.63 M |
Dermata Therapeutics Asset Utilization
One of the ways to look at asset utilization of Dermata is to check how much profit was generated for every dollar of assets it reports. Dermata Therapeutics shows a negative utilization of assets of -1.36 percent, losing $0.0136 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Dermata Therapeutics shows how discouraging it operates for each dollar spent on its assets.Dermata Therapeutics Ownership Allocation
Dermata Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Dermata Therapeutics Profitability Analysis
Net Loss for the year was (12.29 B) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Dermata Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Dermata Therapeutics and how it compares across the competition.
About Dermata Therapeutics Valuation
The stock valuation mechanism determines Dermata Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Dermata Therapeutics. We calculate exposure to Dermata Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Dermata Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | (370.30) | (388.81) |
Dermata Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 1.5 M |
Dermata Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Dermata Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Dermata we look at many different elements of the entity such as Dermata's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Dermata Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Dermata Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Dermata Therapeutics' worth.Complementary Tools for Dermata Stock analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |